Artcline, a Rostock, a Germany-based company advancing novel immune cell-based extracorporeal sepsis therapy, raised EUR4.4M in funding.
In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8M. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6M was implemented. As a result, Artcline received additional equity capital totaling EUR 4.4 million.
Founded in 2007 as a spin-off from the University of Rostock and led by CEO Jens Altrichter, Artcline develops a novel immune cell-based extracorporeal sepsis therapy for patients worldwide. The ARTICE® therapy uses immune cells from healthy blood donors to temporarily take over partial functions and also reactivate the patient’s own immune system.
With the additional funds, Artcline will finance the further execution of the randomized, controlled clinical trial ReActIF-ICE with more than 100 patients with septic shock. The study is currently being conducted in intensive care units in 12 German hospitals and is intended to show not only the safety but also the efficacy of the ARTICE® therapy.
FinSMEs
25/03/2024